Today, Friday, February 14, 2025, Oculis Holding AG (the “Company” or “Oculis”) announced the completion of a share offering of approximately ISK 14.1 billion (USD 100 million). The offering was oversubscribed, with demand from both foreign and Icelandic investors.
Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.
Arctica Finance acted as financial advisor to Oculis’s on the offering and oversaw the sale of shares to Icelandic investors. Other advisors on the offering were BofA Securities, Leerink Partners, and Pareto Securities.
